奥赛康创新药ASKC202在2025年ESMO年会公布临床研究数据

Core Viewpoint - The company announced the presentation of clinical trial data for its new cMET inhibitor ASK202 in combination with Lapatinib at the ESMO annual meeting, indicating potential for effective treatment in patients with advanced non-small cell lung cancer who have failed EGFR-TKI therapy [1] Group 1 - The clinical trial data was presented in poster format at the European Society for Medical Oncology (ESMO) annual meeting held in Berlin on October 18 [1] - The combination of ASK202 (cMET inhibitor) and Lapatinib (third-generation EGFR TKI) aims to provide a solution for lung cancer patients who are resistant to EGFR-TKI, potentially extending their survival [1] - The collaboration of these two innovative drug projects enhances the company's pipeline in the oncology sector, positively impacting its strategic layout [1]